- The Washington Times - Tuesday, December 18, 2018

Sen. Elizabeth Warren on Tuesday became the latest 2020 presidential contender to target soaring prescription costs, saying the U.S. government should act as a generic-drug manufacturer to force down prices.

A bill from Mrs. Warren, Massachusetts Democrat, would set up a manufacturing office within the Department of Health and Human Services to make select drugs and offer them at affordable prices.

She says the generic market is supposed to inject competition into the markets, yet too few companies vie for consumer dollars, leaving prices high.

The industry cannot be trusted to correct itself, she added, as the Department of Justice reportedly investigates a “massive price fixing conspiracy” among generic manufacturers.

“In market after market, competition is dying as a handful of giant companies spend millions to rig the rules, insulate themselves from accountability, and line their pockets at the expense of American families,” Mrs. Warren said. “The solution here is not to replace markets, but to fix them.”



Rep. Jan Schakowsky, Illinois Democrat, introduced a House companion to Mrs. Warren’s bill, dubbed the Affordable Drug Manufacturing Act.

The bill is an ambitious entrant into the collection of ideas that members of Congress and the Trump administration are pitching to bring prescription drug costs down. Voters cite rising drug costs as one of their key concerns. 

“Elizabeth Warren is putting oxygen in the room for a bolder progressive Democratic congressional agenda in 2019 — and her big ideas will dominate the 2020 conversation,” said Stephanie Taylor, co-founder of the Progressive Change Campaign Committee.

Mrs. Warren said her legislation would require the newly created Office of Drug Manufacturing to make generic insulin within one year. The rising price of insulin has sparked a nationwide outcry amid diabetes patients.  

Otherwise, the bill says the government should step in if: No company is making a generic version of a drug when the brand-name patent expires; only one or two companies make the drug and there’s been a price increase or drug shortage; or if only one or two companies make it, the price is a barrier to access and the World Health Organization designates it as an “essential medicine.”

Beyond Mrs. Warren, a series of Democrats who may seek the White House — Sens. Kamala Harris, Jeff Merkley and Amy Klobuchar — introduced a bill last week that would require drug companies to justify any price increase of 10 percent over the past year, 20 percent over the preceding three years or 30 percent over the last five years.

If HHS found the increases unreasonable, it could order the company to reimburse consumers, insurers and public programs such as Medicare and Medicaid and restore the price to its original level, before the price spikes. 

Companies also would face civil penalties.

Sen. Bernard Sanders, Vermont independent and hero to the progressive left, introduced a bill that would punish companies that refuse to charge Americans no more than the median price for the same drugs in countries such as Canada or Germany. It would allow the federal government to authorize a generic version of the drug, regardless of patents or exclusivity rights.

President Trump, meanwhile, is rolling out a drug-pricing blueprint that tends to rely on market-oriented changes, instead of letting the government step in, as prominent liberals are proposing. 

For instance, Mr. Trump wants drug companies to disclose their list prices on television ads.

Some Republicans are wary of a separate idea that would align doctor-administered drugs under Medicare Part B to what other developed nations pay, using an International Pricing Index. 

They say it smacks of pricing controls that are anathema to free-market conservatives, though the administration has defended the idea.

“We take the list price the pharma gives us and we pay 6 percent on top of that,” Health Secretary Alex Azar told Axios at a recent health care event. “We’re a price fixer, we’re just a bad one.”

Sign up for Daily Newsletters

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide